Takeda lowers FY2023 profit forecasts after pipeline setbacks
Setbacks for Exkivity and Alofisel mean Takeda has adjusted its profit outlook; full-year revenue not affected.
26 October 2023
26 October 2023
Setbacks for Exkivity and Alofisel mean Takeda has adjusted its profit outlook; full-year revenue not affected.
Experts discuss the key trends in quality improvements and API reshoring for the generic drugs market at CpHI Europe.
Experts discuss how pharma companies need to consider patient centricity earlier in their development plans.
GSK plans to submit the data to regulatory agencies to support label expansion for Arexvy in the younger adult patient population in 2024.
AxoSim’s microBrain drug discovery platform acquisition includes a US manufacturing facility, and associated patents and IP.
iCARE4CVD is co-ordinated by Maastricht University and Novo Nordisk and aims to collect and analyse data from one million people to validate personalised treatments.
Aiolos will lead the anti-TSLP antibody into Phase II clinical trials after demonstrating high potency in Phase I study.
The AD and PD drug aims to reduce the level of neurotoxic proteins, thereby improving information flow across the axonal transport.
Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.
Join us on November 1st as Cynthia Bheling, Zobair Younossi, Rohit Loompa, and Vipul Jairath provide an overview of the drug development landscape.
Give your business an edge with our leading industry insights.